Flamingo Therapeutics2023-02-14T20:19:39-08:00

We are Focused on
Clinical Execution.

Flamingo has a late-stage pipeline focused on delivering therapeutic benefit to patients living with cancer.  We believe our programs and approach address large unmet medical needs where RNA-targeting can be successful.

Our State-of-the-Art
Chemistries Drive Innovation.

At Flamingo, we understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeutic, especially for difficult to treat cancers, where many modalities have failed to succeed.

Featured News

Flamingo Therapeutics Receives €1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio

Flamingo Therapeutics (“Flamingo”) today announced that it has been awarded a research grant of €1.7 million by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million project.

June 15, 2023|
Go to Top